user: GUEST
width: 600


MyHits has reached its end of life and no longer provides data or services. Thank you for your support and trust for more than 23 years!
However, the webserver will remain online in its present form at least until end of March 2025.
To ensure the future of MyHits, we would be happy if a person or community would take over the resource or parts of it. Interested? Please contact us (myhits [at] sib.swiss).

Pagni M, Ioannidis V, Cerutti L, Zahn-Zabal M, Jongeneel CV, Hau J, Martin O, Kuznetsov D, Falquet L.
MyHits: improvements to an interactive resource for analyzing protein sequences.
Nucleic Acids Res. 2007 Jul; 35(Web Server issue):W433-7

DescriptionRecName: Full=Exosome component 10; EC=3.1.13.-; AltName: Full=Autoantigen PM/Scl 2; AltName: Full=P100 polymyositis-scleroderma overlap syndrome-associated autoantigen; AltName: Full=Polymyositis/scleroderma autoantigen 100 kDa; Short=PM/Scl-100; AltName: Full=Polymyositis/scleroderma autoantigen 2;
MyHits logo
MyHits synonymsEXOSX_HUMAN , Q01780 , B1AKQ0 , B1AKQ1 , Q15158 , A37BDC8F49BF2E57
match map segment
iprf:HRDC ismart:HRDC ipfam:HRDC ismart:35EXOc ipfam:PMC2NT ipfam:DNA_pol_A_exo1  
Legends: 1, Phosphoserine. {ECO:0000244|PubMed:23186163}; 2, CROSSLNK Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1). {ECO:0000244|PubMed:25114211}; 3, CROSSLNK Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2). {ECO:0000244|PubMed:25218447}; 4, CROSSLNK Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2). {ECO:0000244|PubMed:25772364}; 5, HRDC. {ECO:0000255|PROSITE- ProRule:PRU00328}; 6, VAR_SEQ Missing (in isoform 2). {ECO:0000303|PubMed:1644924}; 7, iprf:HRDC [T]; 8, ismart:HRDC [T]; 9, ipfam:HRDC [T]; 10, ipfam:PMC2NT [T]; 11, ipfam:DNA_pol_A_exo1 [T]; 12, HELIX {ECO:0000244|PDB:3SAF}; 13, STRAND {ECO:0000244|PDB:3SAF}; 14, TURN {ECO:0000244|PDB:3SAF}; 15, STRAND {ECO:0000244|PDB:3SAH}; 16, STRAND {ECO:0000244|PDB:2CPR}.
ID   EXOSX_HUMAN             Reviewed;         885 AA.
AC   Q01780; B1AKQ0; B1AKQ1; Q15158;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   02-NOV-2016, entry version 179.
DE   RecName: Full=Exosome component 10;
DE            EC=3.1.13.-;
DE   AltName: Full=Autoantigen PM/Scl 2;
DE   AltName: Full=P100 polymyositis-scleroderma overlap syndrome-associated autoantigen;
DE   AltName: Full=Polymyositis/scleroderma autoantigen 100 kDa;
DE            Short=PM/Scl-100;
DE   AltName: Full=Polymyositis/scleroderma autoantigen 2;
GN   Name=EXOSC10; Synonyms=PMSCL, PMSCL2, RRP6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=1383382; DOI=10.1084/jem.176.4.973;
RA   Bluethner M., Bautz F.A.;
RT   "Cloning and characterization of the cDNA coding for a polymyositis-
RT   scleroderma overlap syndrome-related nucleolar 100-kD protein.";
RL   J. Exp. Med. 176:973-980(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Thymocyte;
RX   PubMed=1644924; DOI=10.1172/JCI115895;
RA   Ge Q., Frank M.B., O'Brien C., Targoff I.N.;
RT   "Cloning of a complementary DNA coding for the 100-kD antigenic
RT   protein of the PM-Scl autoantigen.";
RL   J. Clin. Invest. 90:559-570(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2).
RX   PubMed=11426320; DOI=10.1038/sj.gene.6363745;
RA   Stover C., Endo Y., Takahashi M., Lynch N., Constantinescu C.,
RA   Vorup-Jensen T., Thiel S., Friedl H., Hankeln T., Hall R., Gregory S.,
RA   Fujita T., Schwaeble W.;
RT   "The human gene for mannan-binding lectin-associated serine protease-2
RT   (MASP-2), the effector component of the lectin route of complement
RT   activation, is part of a tightly linked gene cluster on chromosome
RT   1p36.2-3.";
RL   Genes Immun. 2:119-127(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CHARACTERIZATION.
RX   PubMed=10465791; DOI=10.1101/gad.13.16.2148;
RA   Allmang C., Petfalski E., Podtelejnikov A., Mann M., Tollervey D.,
RA   Mitchell P.;
RT   "The yeast exosome and human PM-Scl are related complexes of 3'-->5'
RT   exonucleases.";
RL   Genes Dev. 13:2148-2158(1999).
RN   [8]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12429849; DOI=10.1091/mbc.E02-05-0271;
RA   Scherl A., Coute Y., Deon C., Calle A., Kindbeiter K., Sanchez J.-C.,
RA   Greco A., Hochstrasser D.F., Diaz J.-J.;
RT   "Functional proteomic analysis of human nucleolus.";
RL   Mol. Biol. Cell 13:4100-4109(2002).
RN   [9]
RP   FUNCTION IN NONSENSE-MEDIATED MRNA DECAY, AND SUBCELLULAR LOCATION.
RX   PubMed=14527413; DOI=10.1016/S1097-2765(03)00349-6;
RA   Lejeune F., Li X., Maquat L.E.;
RT   "Nonsense-mediated mRNA decay in mammalian cells involves decapping,
RT   deadenylating, and exonucleolytic activities.";
RL   Mol. Cell 12:675-687(2003).
RN   [10]
RP   PROTEIN INTERACTION.
RX   PubMed=15231747; DOI=10.1101/gr.2122004;
RA   Lehner B., Sanderson C.M.;
RT   "A protein interaction framework for human mRNA degradation.";
RL   Genome Res. 14:1315-1323(2004).
RN   [11]
RP   FUNCTION IN NUCLEAR PRE-MRNA DEGRADATION.
RX   PubMed=16455498; DOI=10.1016/j.molcel.2005.12.008;
RA   West S., Gromak N., Norbury C.J., Proudfoot N.J.;
RT   "Adenylation and exosome-mediated degradation of cotranscriptionally
RT   cleaved pre-messenger RNA in human cells.";
RL   Mol. Cell 21:437-443(2006).
RN   [12]
RP   INTERACTION WITH ALYREF.
RX   PubMed=17234882; DOI=10.1101/gad.1503107;
RA   Yoh S.M., Cho H., Pickle L., Evans R.M., Jones K.A.;
RT   "The Spt6 SH2 domain binds Ser2-P RNAPII to direct Iws1-dependent mRNA
RT   splicing and export.";
RL   Genes Dev. 21:160-174(2007).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH C1D AND MPHOSPH6.
RX   PubMed=17412707; DOI=10.1093/nar/gkm082;
RA   Schilders G., van Dijk E., Pruijn G.J.M.;
RT   "C1D and hMtr4p associate with the human exosome subunit PM/Scl-100
RT   and are involved in pre-rRNA processing.";
RL   Nucleic Acids Res. 35:2564-2572(2007).
RN   [14]
RP   FUNCTION IN MRNA DEGRADATION, AND SUBCELLULAR LOCATION.
RX   PubMed=17545563; DOI=10.1261/rna.575107;
RA   van Dijk E.L., Schilders G., Pruijn G.J.;
RT   "Human cell growth requires a functional cytoplasmic exosome, which is
RT   involved in various mRNA decay pathways.";
RL   RNA 13:1027-1035(2007).
RN   [15]
RP   FUNCTION IN HISTONE MRNA DEGRADATION ACTIVITY.
RX   PubMed=18172165; DOI=10.1101/gad.1622708;
RA   Mullen T.E., Marzluff W.F.;
RT   "Degradation of histone mRNA requires oligouridylation followed by
RT   decapping and simultaneous degradation of the mRNA both 5' to 3' and
RT   3' to 5'.";
RL   Genes Dev. 22:50-65(2008).
RN   [16]
RP   FUNCTION IN PROMPT DEGRADATION.
RX   PubMed=19056938; DOI=10.1126/science.1164096;
RA   Preker P., Nielsen J., Kammler S., Lykke-Andersen S.,
RA   Christensen M.S., Mapendano C.K., Schierup M.H., Jensen T.H.;
RT   "RNA exosome depletion reveals transcription upstream of active human
RT   promoters.";
RL   Science 322:1851-1854(2008).
RN   [17]
RP   ASSOCIATION WITH THE RNA EXOSOME COMPLEX, AND SUBCELLULAR LOCATION.
RX   PubMed=20531386; DOI=10.1038/emboj.2010.121;
RA   Tomecki R., Kristiansen M.S., Lykke-Andersen S., Chlebowski A.,
RA   Larsen K.M., Szczesny R.J., Drazkowska K., Pastula A., Andersen J.S.,
RA   Stepien P.P., Dziembowski A., Jensen T.H.;
RT   "The human core exosome interacts with differentially localized
RT   processive RNases: hDIS3 and hDIS3L.";
RL   EMBO J. 29:2342-2357(2010).
RN   [18]
RP   IDENTIFICATION IN THE RNA EXOSOME COMPLEX, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=20531389; DOI=10.1038/emboj.2010.122;
RA   Staals R.H., Bronkhorst A.W., Schilders G., Slomovic S., Schuster G.,
RA   Heck A.J., Raijmakers R., Pruijn G.J.;
RT   "Dis3-like 1: a novel exoribonuclease associated with the human
RT   exosome.";
RL   EMBO J. 29:2358-2367(2010).
RN   [19]
RP   FUNCTION IN NUCLEAR MRNA SURVEILLANCE.
RX   PubMed=20699273; DOI=10.1093/nar/gkq703;
RA   de Almeida S.F., Garcia-Sacristan A., Custodio N., Carmo-Fonseca M.;
RT   "A link between nuclear RNA surveillance, the human exosome and RNA
RT   polymerase II transcriptional termination.";
RL   Nucleic Acids Res. 38:8015-8026(2010).
RN   [20]
RP   FUNCTION IN RRNA MATURATION.
RX   PubMed=20368444; DOI=10.1073/pnas.0910621107;
RA   Slomovic S., Fremder E., Staals R.H., Pruijn G.J., Schuster G.;
RT   "Addition of poly(A) and poly(A)-rich tails during RNA degradation in
RT   the cytoplasm of human cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:7407-7412(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-821, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-583, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-583, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [25]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-826, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [26]
RP   STRUCTURE BY NMR OF 483-593.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the HRDC domain of human exosome component
RT   10.";
RL   Submitted (NOV-2005) to the PDB data bank.
CC   -!- FUNCTION: Putative catalytic component of the RNA exosome complex
CC       which has 3'->5' exoribonuclease activity and participates in a
CC       multitude of cellular RNA processing and degradation events. In
CC       the nucleus, the RNA exosome complex is involved in proper
CC       maturation of stable RNA species such as rRNA, snRNA and snoRNA,
CC       in the elimination of RNA processing by-products and non-coding
CC       'pervasive' transcripts, such as antisense RNA species and
CC       promoter-upstream transcripts (PROMPTs), and of mRNAs with
CC       processing defects, thereby limiting or excluding their export to
CC       the cytoplasm. The RNA exosome may be involved in Ig class switch
CC       recombination (CSR) and/or Ig variable region somatic
CC       hypermutation (SHM) by targeting AICDA deamination activity to
CC       transcribed dsDNA substrates. In the cytoplasm, the RNA exosome
CC       complex is involved in general mRNA turnover and specifically
CC       degrades inherently unstable mRNAs containing AU-rich elements
CC       (AREs) within their 3' untranslated regions, and in RNA
CC       surveillance pathways, preventing translation of aberrant mRNAs.
CC       It seems to be involved in degradation of histone mRNA. EXOSC10
CC       has 3'-5' exonuclease activity (By similarity). EXOSC10 is
CC       required for nucleolar localization of C1D and probably mediates
CC       the association of SKIV2L2, C1D and MPP6 wth the RNA exosome
CC       involved in the maturation of 5.8S rRNA. {ECO:0000250,
CC       ECO:0000269|PubMed:14527413, ECO:0000269|PubMed:16455498,
CC       ECO:0000269|PubMed:17412707, ECO:0000269|PubMed:17545563,
CC       ECO:0000269|PubMed:18172165, ECO:0000269|PubMed:19056938,
CC       ECO:0000269|PubMed:20368444, ECO:0000269|PubMed:20699273}.
CC   -!- SUBUNIT: Component of the RNA exosome complex. The catalytically
CC       inactive RNA exosome core (Exo-9) complex is believed to associate
CC       with catalytic subunits EXOSC10, and DIS3 or DIS3L in cytoplasmic-
CC       and nuclear-specific RNA exosome complex forms. Interacts with C1D
CC       and MPHOSPH6. Interacts with ALYREF/THOC4.
CC       {ECO:0000269|PubMed:17234882, ECO:0000269|PubMed:17412707,
CC       ECO:0000269|PubMed:20531389}.
CC   -!- INTERACTION:
CC       Q13901:C1D; NbExp=5; IntAct=EBI-358236, EBI-3844053;
CC       P17844:DDX5; NbExp=3; IntAct=EBI-358236, EBI-351962;
CC       Q9Y2L1:DIS3; NbExp=4; IntAct=EBI-358236, EBI-373539;
CC       Q9NPD3:EXOSC4; NbExp=4; IntAct=EBI-358236, EBI-371823;
CC       Q9NQT4:EXOSC5; NbExp=3; IntAct=EBI-358236, EBI-371876;
CC       Q99547:MPHOSPH6; NbExp=4; IntAct=EBI-358236, EBI-373187;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus, nucleolus. Nucleus.
CC       Note=Strongly enriched in the nucleolus and a small amount has
CC       been found in cytoplasm supporting the existence of a nucleolar
CC       RNA exosome complex form.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q01780-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q01780-2; Sequence=VSP_004362;
CC         Note=No experimental confirmation available.;
CC   -!- SIMILARITY: Contains 1 3'-5' exonuclease domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 HRDC domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00328}.
DR   EMBL; X66113; CAA46904.1; -; mRNA.
DR   EMBL; L01457; AAB59352.1; -; mRNA.
DR   EMBL; AJ300188; CAC15569.1; -; Genomic_DNA.
DR   EMBL; AL109811; CAI22106.1; -; Genomic_DNA.
DR   EMBL; AL109811; CAI22107.1; -; Genomic_DNA.
DR   EMBL; CH471130; EAW71679.1; -; Genomic_DNA.
DR   EMBL; BC039901; AAH39901.1; -; mRNA.
DR   EMBL; BC073788; AAH73788.1; -; mRNA.
DR   CCDS; CCDS126.1; -. [Q01780-2]
DR   CCDS; CCDS30584.1; -. [Q01780-1]
DR   PIR; A43920; A43920.
DR   PIR; JH0796; JH0796.
DR   RefSeq; NP_001001998.1; NM_001001998.2. [Q01780-1]
DR   RefSeq; NP_002676.1; NM_002685.3. [Q01780-2]
DR   UniGene; Hs.632368; -.
DR   PDB; 2CPR; NMR; -; A=483-593.
DR   PDB; 3SAF; X-ray; 2.50 A; A/B=180-606.
DR   PDB; 3SAG; X-ray; 2.70 A; A/B=180-606.
DR   PDB; 3SAH; X-ray; 2.65 A; A/B=180-606.
DR   PDBsum; 2CPR; -.
DR   PDBsum; 3SAF; -.
DR   PDBsum; 3SAG; -.
DR   PDBsum; 3SAH; -.
DR   ProteinModelPortal; Q01780; -.
DR   SMR; Q01780; -.
DR   BioGrid; 111403; 75.
DR   DIP; DIP-31249N; -.
DR   IntAct; Q01780; 54.
DR   MINT; MINT-1143843; -.
DR   STRING; 9606.ENSP00000366135; -.
DR   iPTMnet; Q01780; -.
DR   PhosphoSitePlus; Q01780; -.
DR   SwissPalm; Q01780; -.
DR   BioMuta; EXOSC10; -.
DR   DMDM; 8928564; -.
DR   SWISS-2DPAGE; Q01780; -.
DR   EPD; Q01780; -.
DR   MaxQB; Q01780; -.
DR   PaxDb; Q01780; -.
DR   PeptideAtlas; Q01780; -.
DR   PRIDE; Q01780; -.
DR   DNASU; 5394; -.
DR   Ensembl; ENST00000304457; ENSP00000307307; ENSG00000171824. [Q01780-2]
DR   Ensembl; ENST00000376936; ENSP00000366135; ENSG00000171824. [Q01780-1]
DR   GeneID; 5394; -.
DR   KEGG; hsa:5394; -.
DR   UCSC; uc001asa.4; human. [Q01780-1]
DR   CTD; 5394; -.
DR   DisGeNET; 5394; -.
DR   GeneCards; EXOSC10; -.
DR   HGNC; HGNC:9138; EXOSC10.
DR   HPA; CAB037141; -.
DR   HPA; HPA028470; -.
DR   HPA; HPA028484; -.
DR   MIM; 605960; gene.
DR   neXtProt; NX_Q01780; -.
DR   OpenTargets; ENSG00000171824; -.
DR   PharmGKB; PA33464; -.
DR   eggNOG; KOG2206; Eukaryota.
DR   eggNOG; COG0349; LUCA.
DR   GeneTree; ENSGT00390000015408; -.
DR   HOGENOM; HOG000001579; -.
DR   HOVERGEN; HBG051524; -.
DR   InParanoid; Q01780; -.
DR   KO; K12591; -.
DR   OMA; GNKSMSF; -.
DR   OrthoDB; EOG091G03BH; -.
DR   PhylomeDB; Q01780; -.
DR   TreeFam; TF105991; -.
DR   BioCyc; ZFISH:ENSG00000171824-MONOMER; -.
DR   Reactome; R-HSA-6791226; Major pathway of rRNA processing in the nucleolus and cytosol.
DR   ChiTaRS; EXOSC10; human.
DR   EvolutionaryTrace; Q01780; -.
DR   GeneWiki; Exosome_component_10; -.
DR   GenomeRNAi; 5394; -.
DR   PRO; PR:Q01780; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000171824; -.
DR   CleanEx; HS_EXOSC10; -.
DR   ExpressionAtlas; Q01780; baseline and differential.
DR   Genevisible; Q01780; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0000178; C:exosome (RNase complex); IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0000176; C:nuclear exosome (RNase complex); IEA:InterPro.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0035327; C:transcriptionally active chromatin; IMP:UniProtKB.
DR   GO; GO:0000175; F:3'-5'-exoribonuclease activity; EXP:Reactome.
DR   GO; GO:0004532; F:exoribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0000166; F:nucleotide binding; IEA:InterPro.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0071034; P:CUT catabolic process; IMP:UniProtKB.
DR   GO; GO:0009048; P:dosage compensation by inactivation of X chromosome; IEA:Ensembl.
DR   GO; GO:0071044; P:histone mRNA catabolic process; IMP:UniProtKB.
DR   GO; GO:0000460; P:maturation of 5.8S rRNA; IMP:UniProtKB.
DR   GO; GO:0071028; P:nuclear mRNA surveillance; IMP:UniProtKB.
DR   GO; GO:0071035; P:nuclear polyadenylation-dependent rRNA catabolic process; IMP:UniProtKB.
DR   GO; GO:0071048; P:nuclear retention of unspliced pre-mRNA at the site of transcription; IMP:UniProtKB.
DR   GO; GO:0000956; P:nuclear-transcribed mRNA catabolic process; IMP:UniProtKB.
DR   GO; GO:0000184; P:nuclear-transcribed mRNA catabolic process, nonsense-mediated decay; IMP:UniProtKB.
DR   GO; GO:0006364; P:rRNA processing; TAS:Reactome.
DR   Gene3D; 3.30.420.10; -; 1.
DR   InterPro; IPR002562; 3'-5'_exonuclease_dom.
DR   InterPro; IPR012588; Exosome-assoc_fac_Rrp6_N.
DR   InterPro; IPR010997; HRDC-like.
DR   InterPro; IPR002121; HRDC_dom.
DR   InterPro; IPR012337; RNaseH-like_dom.
DR   Pfam; PF01612; DNA_pol_A_exo1; 1.
DR   Pfam; PF00570; HRDC; 1.
DR   Pfam; PF08066; PMC2NT; 1.
DR   SMART; SM00474; 35EXOc; 1.
DR   SMART; SM00341; HRDC; 1.
DR   SUPFAM; SSF47819; SSF47819; 1.
DR   SUPFAM; SSF53098; SSF53098; 1.
DR   PROSITE; PS50967; HRDC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Exonuclease; Exosome; Hydrolase; Isopeptide bond;
KW   Nonsense-mediated mRNA decay; Nuclease; Nucleus; Phosphoprotein;
KW   Reference proteome; RNA-binding; rRNA processing; Ubl conjugation.
FT   CHAIN         1    885       Exosome component 10.
FT                                /FTId=PRO_0000087133.
FT   DOMAIN      503    583       HRDC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00328}.
FT   MOD_RES     821    821       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK    583    583       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK    583    583       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447}.
FT   CROSSLNK    826    826       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25772364}.
FT   VAR_SEQ     695    719       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:1644924}.
FT                                /FTId=VSP_004362.
FT   HELIX       183    186       {ECO:0000244|PDB:3SAF}.
FT   STRAND      194    196       {ECO:0000244|PDB:3SAF}.
FT   HELIX       214    216       {ECO:0000244|PDB:3SAF}.
FT   HELIX       218    220       {ECO:0000244|PDB:3SAF}.
FT   STRAND      253    255       {ECO:0000244|PDB:3SAF}.
FT   HELIX       259    263       {ECO:0000244|PDB:3SAF}.
FT   HELIX       269    272       {ECO:0000244|PDB:3SAF}.
FT   HELIX       283    285       {ECO:0000244|PDB:3SAF}.
FT   STRAND      288    291       {ECO:0000244|PDB:3SAF}.
FT   HELIX       294    304       {ECO:0000244|PDB:3SAF}.
FT   STRAND      308    317       {ECO:0000244|PDB:3SAF}.
FT   STRAND      325    332       {ECO:0000244|PDB:3SAF}.
FT   STRAND      337    341       {ECO:0000244|PDB:3SAF}.
FT   TURN        342    345       {ECO:0000244|PDB:3SAF}.
FT   HELIX       346    352       {ECO:0000244|PDB:3SAF}.
FT   HELIX       353    356       {ECO:0000244|PDB:3SAF}.
FT   STRAND      361    367       {ECO:0000244|PDB:3SAF}.
FT   HELIX       369    379       {ECO:0000244|PDB:3SAF}.
FT   STRAND      384    388       {ECO:0000244|PDB:3SAF}.
FT   HELIX       389    395       {ECO:0000244|PDB:3SAF}.
FT   HELIX       403    411       {ECO:0000244|PDB:3SAF}.
FT   TURN        418    421       {ECO:0000244|PDB:3SAF}.
FT   HELIX       431    442       {ECO:0000244|PDB:3SAF}.
FT   HELIX       444    458       {ECO:0000244|PDB:3SAF}.
FT   STRAND      461    463       {ECO:0000244|PDB:3SAH}.
FT   HELIX       464    476       {ECO:0000244|PDB:3SAF}.
FT   HELIX       490    492       {ECO:0000244|PDB:3SAF}.
FT   HELIX       493    496       {ECO:0000244|PDB:3SAF}.
FT   STRAND      497    500       {ECO:0000244|PDB:2CPR}.
FT   HELIX       504    524       {ECO:0000244|PDB:3SAF}.
FT   HELIX       528    531       {ECO:0000244|PDB:3SAF}.
FT   HELIX       534    543       {ECO:0000244|PDB:3SAF}.
FT   HELIX       548    552       {ECO:0000244|PDB:3SAF}.
FT   STRAND      555    557       {ECO:0000244|PDB:3SAH}.
FT   HELIX       560    564       {ECO:0000244|PDB:3SAF}.
FT   HELIX       566    577       {ECO:0000244|PDB:3SAF}.
FT   HELIX       583    586       {ECO:0000244|PDB:3SAF}.
CC   --------------------------------------------------------------------------
CC   The following FT lines are automated annotations from the MyHits database.
CC   --------------------------------------------------------------------------
FT   MYHIT       503    583       iprf:HRDC [T]
FT   MYHIT       503    583       ismart:HRDC [T]
FT   MYHIT       506    572       ipfam:HRDC [T]
FT   MYHIT       288    456       ismart:35EXOc [T]
FT   MYHIT        44    133       ipfam:PMC2NT [T]
FT   MYHIT       289    455       ipfam:DNA_pol_A_exo1 [T]
SQ   SEQUENCE   885 AA;  100831 MW;  A37BDC8F49BF2E57 CRC64;
     MAPPSTREPR VLSATSATKS DGEMVLPGFP DADSFVKFAL GSVVAVTKAS GGLPQFGDEY
     DFYRSFPGFQ AFCETQGDRL LQCMSRVMQY HGCRSNIKDR SKVTELEDKF DLLVDANDVI
     LERVGILLDE ASGVNKNQQP VLPAGLQVPK TVVSSWNRKA AEYGKKAKSE TFRLLHAKNI
     IRPQLKFREK IDNSNTPFLP KIFIKPNAQK PLPQALSKER RERPQDRPED LDVPPALADF
     IHQQRTQQVE QDMFAHPYQY ELNHFTPADA VLQKPQPQLY RPIEETPCHF ISSLDELVEL
     NEKLLNCQEF AVDLEHHSYR SFLGLTCLMQ ISTRTEDFII DTLELRSDMY ILNESLTDPA
     IVKVFHGADS DIEWLQKDFG LYVVNMFDTH QAARLLNLGR HSLDHLLKLY CNVDSNKQYQ
     LADWRIRPLP EEMLSYARDD THYLLYIYDK MRLEMWERGN GQPVQLQVVW QRSRDICLKK
     FIKPIFTDES YLELYRKQKK HLNTQQLTAF QLLFAWRDKT ARREDESYGY VLPNHMMLKI
     AEELPKEPQG IIACCNPVPP LVRQQINEMH LLIQQAREMP LLKSEVAAGV KKSGPLPSAE
     RLENVLFGPH DCSHAPPDGY PIIPTSGSVP VQKQASLFPD EKEDNLLGTT CLIATAVITL
     FNEPSAEDSK KGPLTVAQKK AQNIMESFEN PFRMFLPSLG HRAPVSQAAK FDPSTKIYEI
     SNRWKLAQVQ VQKDSKEAVK KKAAEQTAAR EQAKEACKAA AEQAISVRQQ VVLENAAKKR
     ERATSDPRTT EQKQEKKRLK ISKKPKDPEP PEKEFTPYDY SQSDFKAFAG NSKSKVSSQF
     DPNKQTPSGK KCIAAKKIKQ SVGNKSMSFP TGKSDRGFRY NWPQR
//